Navigation Links
Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
Date:4/15/2008

ipilimumab administered on the first day of the

28-day cycle for up to four cycles. Ipilimumab dosing initially ranged

from 0.5 mg/kg to 3 mg/kg. Additional patients are now being treated

with higher doses (5 mg/kg and 10 mg/kg) of ipilimumab. The treatment

combination was generally well-tolerated. Adverse events associated

with ipilimumab treatment are consistent with data previously reported

from this study and from other clinical trials of ipilimumab.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com.

Medarex Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed herein relating to the interim data from ongoing ipilimumab combination Phase 1 studies may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... -- Organovo Holdings, Inc. (NYSE MKT: ONVO) today announced preliminary ... year ended March 31, 2015. Based on ... March 31, 2015, Organovo estimates: , Total ... and approximately $571 thousand for the fiscal year , ... and fiscal year ended March 31, 2015 of approximately ...
(Date:4/21/2015)... --Algae International Group, Inc. ( ALGA ), through its ... exceptional Hempster T-Shirt sales following yesterday,s online sales launch. ... introduced four t-shirt designs specific to the ,Hempster Clothing, ... the online sales of these first four t-shirts over ... to the  Marijuana Policy Project  (MPP), an organization dedicated ...
(Date:4/21/2015)... April 21, 2015 Global cap ... World demand for caps and closures will exceed $55 billion ... exceed two trillion annually. Beverages will continue to account for ... and a number of smaller markets are expected to register ... Although the most developed markets -- the US, ...
Breaking Medicine Technology:Organovo Holdings, Inc. Pre-Announces Preliminary Fiscal 2015 Fourth Quarter And Year End Financial Information 2Organovo Holdings, Inc. Pre-Announces Preliminary Fiscal 2015 Fourth Quarter And Year End Financial Information 3Organovo Holdings, Inc. Pre-Announces Preliminary Fiscal 2015 Fourth Quarter And Year End Financial Information 4American Seed & Oil Company 420 Hempster T-Shirt Sales Soar; Online Sales Launched Yesterday with Start of 420 Week; Over 2000 Shirts Sold So Far 2World Caps & Closures Market 2World Caps & Closures Market 3
(Date:4/21/2015)... Displays & Exhibits, Inc. a division of Absolute ... building industry, announced a management change of the retail ... in Tustin, California.“It is very important to have a ... in quality as offered by overseas trade show accessories ... Adduru is the new manager of Displays & Exhibits ...
(Date:4/21/2015)... Henry Mayo Newhall Hospital, located in California’s ... to automatically send continuation of care documents (CCDs). When ... communication with clinics and other ambulatory practices, they selected ... , “Provider Alert will enable the physician offices ... need to provide continuing care in real time,” said ...
(Date:4/21/2015)... Dallas, Texas (PRWEB) April 22, 2015 ... Pipeline Review, H1 2015” provides comparative analysis ... The report strengthens R&D pipelines by identifying ... and best-in-class products. Complete report with TOC ... , The report also reviews key players ...
(Date:4/21/2015)... 21, 2015 The report ... comparative analysis on the therapeutic development for ... identifying new targets and MOAs to produce ... TOC is available @ http://www.rnrmarketresearch.com/sinusitis-pipeline-review-h1-2015-market-report.html ... players involved in the therapeutic development for ...
(Date:4/21/2015)... Information is the best weapon in the fight for your ... their families with knowledge about living with cancer in his ... Answer" and new website . , In the book, ... diagnosis through treatment and even death. The goal, he says, ... home and in the examination room. , “Cancer patients and ...
Breaking Medicine News(10 mins):Health News:Displays & Exhibits Reveals Tustin, California Showroom Under New Management 2Health News:Henry Mayo Newhall Hospital to Improve Ambulatory Information Sharing with Summit Healthcare's Summit Provider Alert 2Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Authoritative guide and new accompanying therapeutic web portal bridge information gaps in cancer treatment 2
... The following is being issued by Cheryl ... 721 will streamline the health care process for ... long waits and associated, unnecessary costs because they ... treatment."Currently, patients seeking rehabilitation for functional impairments due ...
... experts say, , , THURSDAY, March 5 (HealthDay News) -- Men ... life span by more than two years, Swedish researchers say. ... beneficial effect on length of life as quitting smoking in ... exercise, the researchers said. But Dr. Karl Michaëlsson, a senior ...
... Group, Inc. (OTC Bulletin Board: POLGA ; OTC ... marketer of engineered materials, announced today it will release ... of the market on Wednesday, March 18, 2009. Company ... slides, starting at 10:00 a.m. EDT on Thursday, March ...
... March 5 Despite dermatologists, continual efforts, ... harmful effects of excessive sun exposure and regular use ... to reduce the risk of developing skin cancer. But ... may help encourage them to apply sunscreen regularly via ...
... BRIARCLIFF MANOR, N.Y., March 5 SETO Holdings, Inc. (Pink ... under which it agreed in principle (1) to issue shares ... stock of Advanced Hearing Centers, Inc. ("AHC"), a Maryland corporation ... locations in Maryland and one in Virginia, and (2) to ...
... of infection, study says , , THURSDAY, March 5 (HealthDay News) ... existing vaccines so that they can protect people during a ... ,killer T-cell, is the hit-man of the immune system. It ... body, helping rid us of infections," the study,s lead author, ...
Cached Medicine News:Health News:Men Who Get Active in Midlife Live Longer 2Health News:Men Who Get Active in Midlife Live Longer 3Health News:Polymer Group, Inc. Announces Fourth Quarter and Year-End 2008 Earnings Conference Call 2Health News:New Study Finds Text-Messaging Reminders Effective in Improving Adherence to Sunscreen Use 2Health News:New Study Finds Text-Messaging Reminders Effective in Improving Adherence to Sunscreen Use 3Health News:New Study Finds Text-Messaging Reminders Effective in Improving Adherence to Sunscreen Use 4Health News:SETO Holdings, Inc. Signs Letter of Intent to Dispose of all its Existing Businesses and Acquire Advanced Hearing Centers, Inc.; New Management to be Installed. 2
Used for the introduction of catheters, balloons and other vascular devices....
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used for contralateral access to the iliac artery for interventional procedures after initial wire guide positioning has been established....
Used to introduce balloon, electrode, closed or non-tapered end and other catheters....
Medicine Products: